Toll-like receptor 3 ligand polyinosinic:polycytidylic acid enhances autoimmune disease in a retinal autoimmunity model

International Immunopharmacology

Volumn 11, Issue 6, 2011, Pages 769-773

  Ren, Xiangrong ^a   Zhou, Hongyan ^a   Li, Bing ^a   Su, Shao Bo ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Autoimmune disease; Interleukin 17; Polyinosinic:polycytidylic acid; Toll like receptor 3; Uveitis

Indexed keywords

DOUBLE STRANDED RNA; GAMMA INTERFERON; INTERLEUKIN 17; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE UVEITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; INNATE IMMUNITY; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC THERAPY; T LYMPHOCYTE; UVEITIS;

ANIMALS; AUTOIMMUNE DISEASES; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HYPERSENSITIVITY, DELAYED; INTERFERON-GAMMA; INTERLEUKIN-17; MICE; MICE, INBRED STRAINS; POLY I-C; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 3; UVEITIS;

EID: 79955870871     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.01.019     Document Type: Article

References (46)

1. Patole PS, Grone HJ, Segerer S, Ciubar R, Belemezova E, Henger A, et al. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 2005;16:1326-38. (Pubitemid 41716517)
2. Zipris D, Lien E, Xie JX, Greiner DL, Mordes JP, Rossini AA. TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats. J Immunol 2005;174:131-42. (Pubitemid 40007399)
3. Li M, Zhou Y, Feng G, Su SB. The critical role of Toll-like receptor signaling pathways in the induction and progression of autoimmune diseases. Curr Mol Med 2009;9:365-74.
4. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76. (Pubitemid 37174535)
5. Kawai T, Akira S. TLR signaling. Semin Immunol 2007;19:24-32. (Pubitemid 46498752)
6. Foster SL, Medzhitov R. Gene-specific control of the TLR-induced inflammatory response. Clin Immunol 2009;130:7-15.
7. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95. (Pubitemid 41057715)
8. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak- Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7. (Pubitemid 34406754)
9. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006;6:823-35. (Pubitemid 44631651)
10. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005;52:2656-65. (Pubitemid 41369093)
11. Roelofs MF, Wenink MH, Brentano F, Abdollahi-Roodsaz S, Oppers-Walgreen B, Barrera P, et al. Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA). Ann Rheum Dis 2009;68:1486-93.
12. Holm CK, Petersen CC, Hvid M, Petersen L, Paludan SR, Deleuran B, et al. TLR3 ligand polyinosinic:polycytidylic acid induces IL-17A and IL-21 synthesis in human Th cells. J Immunol 2009;183:4422-31.
13. Caspi RR. Ocular autoimmunity: the price of privilege? Immunol Rev 2006;213:23-35.
14. Caspi RR, Roberge FG, Chan CC, Wiggert B, Chader GJ, Rozenszajn LA, et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 1988;140:1490-5.
15. Agarwal RK, Caspi RR. Rodent models of experimental autoimmune uveitis. Meth Mol Med 2004;102:395-419.
16. Su SB, Silver PB, Grajewski RS, Agarwal RK, Tang J, Chan CC, et al. Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity. J Immunol 2005;175:6303-10.
17. Fang J, Fang D, Silver PB, Wen F, Li B, Ren X, et al. The role of TLR2, TRL3, TRL4, and TRL9 signaling in the pathogenesis of autoimmune disease in a retinal autoimmunity model. Investig Ophthalmol Vis Sci 2010;51:3092-9.
18. Pepperberg DR, Okajima TL, Ripps H, Chader GJ, Wiggert B. Functional properties of interphotoreceptor retinoid-binding protein. Photochem Photobiol 1991;54:1057-60.
19. Caspi RR, Sun B, Agarwal RK, Silver PB, Rizzo LV, Chan CC, et al. T cell mechanisms in experimental autoimmune uveoretinitis: susceptibility is a function of the cytokine response profile. Eye (Lond) 1997;11(Pt 2):209-12. (Pubitemid 27249914)
20. Chan CC, Caspi RR, Ni M, Leake WC, Wiggert B, Chader GJ, et al. Pathology of experimental autoimmune uveoretinitis in mice. J Autoimmun 1990;3:247-55. (Pubitemid 20337655)
21. Snedecor G, Cochran W. Statistical methods. Ames, IA: Iowa State University Press; 1967.
22. Niller HH, Wolf H, Minarovits J. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 2008;41:298-328. (Pubitemid 351593860)
23. Kariko K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004;279:12542-50. (Pubitemid 38445825)
24. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med 2009;15:410-6.
25. Trompette A, Divanovic S, Visintin A, Blanchard C, Hegde RS, Madan R, et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature 2009;457:585-8.
26. Sel S, Wegmann M, Sel S, Bauer S, Garn H, Alber G, et al. Immunomodulatory effects of viral TLR ligands on experimental asthma depend on the additive effects of IL-12 and IL-10. J Immunol 2007;178:7805-13. (Pubitemid 46898052)
27. Camateros P, Tamaoka M, Hassan M, Marino R, Moisan J, Marion D, et al. Chronic asthma-induced airway remodeling is prevented by toll-like receptor-7/8 ligand S28463. Am J Respir Crit Care Med 2007;175:1241-9. (Pubitemid 46905749)
28. Aumeunier A, Grela F, Ramadan A, Pham Van L, Bardel E, Gomez Alcala A, et al. Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice. PLoS ONE 2010;5:e11484.
29. Yarilina A, DiCarlo E, Ivashkiv LB. Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs. J Immunol 2007;178:2204-11. (Pubitemid 46233418)
30. Touil T, Fitzgerald D, Zhang GX, Rostami A, Gran B. Cutting edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta. J Immunol 2006;177:7505-9. (Pubitemid 44846263)
31. Tzima S, Victoratos P, Kranidioti K, Alexiou M, Kollias G. Myeloid heme oxygenase- 1 regulates innate immunity and autoimmunity by modulating IFN-beta production. J Exp Med 2009;206:1167-79.
32. Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 2008;60:805-12.
33. Trivedi S, Greidinger EL. Endosomal Toll-like receptors in autoimmunity: mechanisms for clinical diversity. Therapy 2009;6:433-42.
34. Nussenblatt R, Whitcup S. Uveitis: fundamentals and clinical practice. Philadelphia: Mosby Elsevier; 2004.
35. Tarrant TK, Silver PB, Chan CC, Wiggert B, Caspi RR. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis. J Immunol 1998;161:122-7. (Pubitemid 28285514)
36. Yokoi H, Kato K, Kezuka T, Sakai J, Usui M, Yagita H, et al. Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin- 12. Eur J Immunol 1997;27:641-6. (Pubitemid 27110574)
37. Su SB, Grajewski RS, Luger D, Agarwal RK, Silver PB, Tang J, et al. Altered chemokine profile associated with exacerbated autoimmune pathology under conditions of genetic interferon-gamma deficiency. Investig Ophthalmol Vis Sci 2007;48:4616-25. (Pubitemid 351260979)
38. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8:500-8. (Pubitemid 34546753)
39. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/ STAT1. Nat Med 2007;13:711-8. (Pubitemid 46889754)
40. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999;162:1246-51. (Pubitemid 29306992)
41. Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: adversaries and collaborators. Ann NY Acad Sci 2010;1183:211-21.
42. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171:6173-7. (Pubitemid 37467240)
43. Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005;237:123-30. (Pubitemid 43117208)
44. Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008;205:799-810. (Pubitemid 351549879)
45. Haak S, Croxford AL, Kreymborg K, Heppner FL, Pouly S, Becher B, et al. IL-17A and IL-17 F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest 2009;119:61-9.
46. Yoshimura T, Sonoda KH, Miyazaki Y, Iwakura Y, Ishibashi T, Yoshimura A, et al. Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis. Int Immunol 2008;20:209-14. (Pubitemid 351234388)